After the Tick Bite: What Clinicians Need to Know

The 4-Day Critical Window: Why Timing Is the First Clinical Decision

Borrelia burgdorferi, the causative organism of Lyme disease, resides in the hind gut of the tick during quiescence. When the tick begins a blood meal, the presence of blood in the tick’s intestines mobilizes the spirochetes, which migrate to the salivary glands and can then be injected into the host. This process takes time, which is why prompt tick removal matters. However, clinicians should be aware that partially-fed ticks, those that have already taken a partial blood meal from another animal or host, may already have spirochetes positioned in the salivary glands and can transmit Borrelia more rapidly upon reattachment [1].

Other co-infecting pathogens operate on shorter transmission timelines. Rickettsia species and Powassan virus can both be transmitted rapidly – in the case of Powassan, within as little as 15 minutes of attachment [2,3]. By the time a clinician sees a patient who has found an attached tick, transmission of certain organisms may have already occurred, regardless of how quickly the tick was removed.

If Borrelia infection goes unrecognized and unaddressed, spirochetes can disseminate into the cerebrospinal fluid within weeks of initial infection [4]. Multi-system involvement follows, with inflammatory, neurological, cardiac, and joint sequelae. Chronic tick-borne disease is significantly more difficult to address clinically than early infection. The biological case for detection in the acute window is direct.

What This Means for Testing

A tick bite testing protocol in the acute phase should prioritize direct detection and should not use a negative serological result to exclude infection. The antibody lag window renders standard serological testing diagnostically unreliable in the first 3 to 6 weeks post-exposure. Direct detection methods, those that detect the pathogen’s own genetic material or antigens rather than the host’s antibody response, are better suited to this period. Baseline laboratory monitoring with CBC and liver function tests can provide early signals for co-infections such as Anaplasma and Ehrlichia, which produce characteristic hematologic changes.

Clinical Presentation: Why Lyme Disease and Co-Infections Are Frequently Missed

Lyme disease and the co-infections transmitted by the same ticks present with overlapping, nonspecific symptoms that do not consistently point toward a single diagnosis. Clinicians who see these patients in the acute phase often encounter a symptom picture that mimics viral illness, allergic response, autoimmune conditions, or other common diagnoses. This is not incidental – it is a consistent pattern documented across clinical series.

Borrelia infection progresses in stages. Early localized disease presents with flu-like symptoms including fatigue, fever, chills, headache, muscle aches, and possible neck pain, with or without an erythema migrans (EM) rash. Early disseminated disease can involve Lyme carditis, lymphocytoma, facial palsy, joint stiffness, and Lyme neuroborreliosis. Late or chronic disseminated disease presents with persistent, cyclic, multi-system symptoms, severe arthritis typically involving one knee, and neuropsychiatric manifestations attributable to the pathogen’s capacity to cross the blood-brain barrier.

Co-infections complicate this presentation substantially. A patient carrying multiple tick-borne pathogens simultaneously will present with overlapping and compounding symptoms that can shift the entire clinical picture. A survey of more than 3,000 patients with chronic Lyme disease found that over 50% had at least one co-infection and 30% had two or more [5]. Babesia was the most frequently identified co-infection, followed closely by Bartonella.

Each co-infecting organism has its own characteristic onset timing and clinical signature:

These co-infections are frequently misattributed to other diagnoses when clinicians encounter them without a confirmed tick exposure history. Babesia is commonly misdiagnosed as anemia, malaria, heart failure, lupus, or MS. Bartonella is frequently misattributed to schizophrenia, ADHD, OCD, autism, or depression, particularly in pediatric patients. Borrelia itself is misdiagnosed as Alzheimer’s disease, ALS, heart failure, or rheumatoid arthritis in chronic presentations.

The more co-infecting pathogens are present, the more synergistically they contribute to immune dysregulation and inflammation. Multi-pathogen infections are generally associated with more severe illness, broader symptom distribution, and more complex and prolonged clinical courses [6].

What This Means for Testing

Co-infection testing tick bite workups should begin at the first clinical encounter, not after a single-pathogen result returns. A single-pathogen testing approach is not appropriate for tick-borne disease in either the acute or chronic setting. The co-infection prevalence data, combined with overlapping symptom patterns, supports a comprehensive testing strategy that evaluates Borrelia, Babesia, and Bartonella simultaneously, along with Anaplasma, Ehrlichia, and Rickettsia where clinical or epidemiological context warrants. Standard CBC and liver function tests provide early signal for Anaplasma, Ehrlichia, and Rickettsia and should not be overlooked in the acute workup. Because Rickettsia (Rocky Mountain spotted fever) and Anaplasma/Ehrlichia can be life-threatening, any combination of sudden high fever, severe headache, and hematologic abnormalities in the context of tick exposure warrants urgent clinical attention.

The EM Rash: Diagnostic Significance and Its Limits in Practice

The classic bullseye presentation, concentric rings radiating from the bite site, appears in fewer than 20% of Lyme disease cases, with some published studies reporting rates as low as 6% [7]. The more common presentation is a solid pink or red area that can be mistaken for an insect bite, contact dermatitis, or cellulitis. A vesicular or blistering rash at or near the bite site may suggest Bartonella co-infection and warrants evaluation accordingly. Approximately 20-30% of patients with confirmed Lyme disease develop no rash at all [8]

Clinicians should also note that EM rashes are typically asymptomatic at the skin surface. They are often not warm, tender, or raised in a way that would independently prompt a patient to seek care. This contributes to cases being missed or dismissed until the infection has disseminated.

What This Means for Testing

When an EM rash is observed, the diagnostic question is no longer whether Lyme disease is present, it is what co-infections may also be present. Testing should focus on co-infection evaluation and baseline laboratory monitoring rather than on confirming the Borrelia diagnosis the rash already provides. A negative serological result in this context does not change the clinical picture. Direct detection methods can still be used to document organism presence in the submitted sample or to evaluate for co-infecting pathogens where clinical concern exists.

Why Standard Lyme Disease Testing After a Tick Bite Is Structurally Limited in the Acute Phase

The standard approach for Lyme disease testing in most clinical settings is the CDC-recommended two-tier algorithm: an initial ELISA, followed by a Western blot if the ELISA is positive or equivocal. This approach is serological, it detects the host antibody response to Borrelia, not the organism itself.

The structural limitations of this approach in the acute setting are well-documented. One analysis found that up to 75% of Lyme disease cases were missed using CDC-recommended methodology [9]. A separate review reported a detection rate of approximately 54% across confirmed cases [10]. Part of this gap is attributable to antibody timing. IgM antibodies peak at approximately 3 weeks post-infection. IgG antibodies peak around 6 weeks [11]. Testing before these windows have elapsed produces negative results in patients with confirmed early infection, not because the test failed technically, but because the biology has not yet generated what the test is designed to detect.

Strain coverage represents an additional structural gap. The standard two-tier assay is designed to detect Borrelia burgdorferi sensu stricto. It does not reliably detect the multiple B. burgdorferi sensu lato genospecies now recognized as causative agents of Lyme borreliosis across North America and Europe, nor does it address tick-borne relapsing fever caused by other Borrelia species [12] A negative result on the standard two-tier algorithm cannot rule out Lyme disease attributable to these additional species.

Perhaps the most significant gap in co-infection terms is that the two-tier algorithm does not test for Babesia, Bartonella, Ehrlichia, Anaplasma, Rickettsia, Mycoplasma, or Powassan virus. A clinician who orders standard Lyme serology and receives a negative result has not tested for any of the co-infections that the same tick may have transmitted simultaneously. These are separate clinical questions requiring separate testing.

What This Means for Testing

A negative standard two-tier test in the acute phase should be recognized as an expected methodological result, not as evidence that infection is absent. Acute Lyme disease testing with standard serology cannot answer whether infection is present during the first 3 to 6 weeks post-exposure, the biology and timing do not allow it to produce meaningful information in that window. Specialty laboratory testing using direct detection methods and broader species coverage provides more actionable information during this period. Standard testing may have a defined role in follow-up evaluation at 3 to 6 weeks post-exposure, when antibody titers are more interpretable.

Direct vs. Indirect Detection: The Diagnostic Foundation of a Tick Bite Testing Protocol

Understanding the distinction between direct and indirect testing is foundational to interpreting results accurately and selecting the right method at the right time. These categories measure fundamentally different biological signals, and no single test provides the complete diagnostic picture.

Direct testing detects the pathogen itself: its DNA (via PCR or digital PCR), its RNA (via FISH), or specific antigens it sheds into host tissue or urine. Because direct testing does not depend on the host immune response, it can detect infection during the acute phase, before antibodies have formed. A positive direct result confirms that the pathogen’s material was present in the submitted sample at the time of collection.

Indirect testing detects the host immune response to the pathogen, specifically the IgG and IgM antibodies produced when the immune system encounters the organism. A positive indirect result indicates that the patient’s immune system has responded to the pathogen. It does not, on its own, distinguish between current pathogen presence and prior exposure. Indirect testing is most interpretable once antibody titers have reached detectable thresholds, which in tick-borne disease is generally 3 to 6 weeks after infection.

A useful framework for thinking about direct testing is sampling probability. A direct test can only identify what is present in the blood collected at the time of the draw. Tick-borne pathogens circulate at low abundance and may not be present in detectable concentrations in every blood draw. A negative direct test result means the organism was not detected in the submitted sample at that moment. It does not confirm that the organism is absent from the patient.

This is why Galaxy Diagnostics recommends a three-day serial draw protocol for its digital PCR testing. Patients are approximately 2.5 times more likely to have a detected result on a triple-draw collection than on a single draw [13]. In cases where pathogen DNA was detected across a triple draw, it was frequently positive on only one of the three draws, underscoring the variability of low-abundance organisms in circulation. 

Digital PCR (dPCR) improves sensitivity over standard quantitative PCR (qPCR) by partitioning each blood sample into thousands of individual reaction chambers. Each partition is read independently as positive or negative, allowing absolute quantification of target DNA even at concentrations that fall below the detection threshold of standard qPCR. In the context of acute tick-borne disease, where pathogen burden in blood may be low, this sensitivity difference is clinically meaningful.

What This Means for Testing

In a tick bite testing protocol, direct vs. indirect Lyme testing are not interchangeable, they are complementary tools applied at different points on the clinical timeline. In the acute phase, direct detection methods are more appropriate than serological approaches because they do not depend on an immune response the patient has not yet mounted. A negative direct test result during the acute window should be interpreted within the full clinical context: the patient’s symptom pattern, timing of exposure, and whether serial sampling was used. Indirect testing has a defined role in follow-up evaluation at 3 to 6 weeks post-bite, when serological results become more interpretable.

How to Structure a Tick Bite Testing Protocol After Exposure

For clinicians managing a patient with a known or suspected tick bite, the following considerations may help structure early diagnostic decision-making. The goal is to match the testing method to the clinical question, account for the timing of the exposure, and assess for co-infection from the beginning rather than sequentially.

Clinical framing questions for a tick bite testing protocol:

• What is the timing of the exposure relative to testing? If the patient presents within the first 3 to 6 weeks of a known tick bite, serological testing is unlikely to yield actionable information. Direct detection methods should be prioritized.
• What pathogens could have been transmitted? A single bite can transmit multiple organisms simultaneously. Testing limited to Borrelia alone will miss co-infections that may be shaping the clinical presentation. Testing should reflect geographic distribution of tick species and the full range of pathogens they carry.
• Is an EM rash present? If yes, this constitutes a clinical diagnosis of Lyme disease. The testing question shifts to co-infection evaluation. A negative serological result does not alter this clinical assessment.
• Are there laboratory signals pointing to specific co-infections? Leukopenia, thrombocytopenia, and elevated liver enzymes in the context of fever and headache following tick exposure warrant urgent consideration of Anaplasma, Ehrlichia, or Rickettsia. CBC and liver function tests should be part of the early workup and repeated at intervals if symptoms evolve.
• Has a serial draw approach been considered? Given the low abundance and intermittent circulation of tick-borne pathogens, a single blood draw may not be sufficient for direct detection. Serial sampling improves detection probability in patients with low pathogen burden.

Galaxy Diagnostics’ Lyme Borrelia Direct Detect (urine antigen test) detects antigen shed by Borrelia burgdorferi, in urine. In a published study of patients with confirmed EM rash, the test demonstrated 100% sensitivity for detecting Borrelia antigen in the submitted samples [14]. It can be ordered as early as days 5 to 7 following tick exposure, making it one of the earliest-available direct detection options in the tick bite testing protocol window. For pediatric patients, the urine collection format offers a practical advantage over blood-based testing in an already stressful clinical encounter.

Galaxy’s BBB Direct Detect (dPCR) assay is designed for molecular detection of Borrelia, Bartonella, and Babesia simultaneously, using a three-day serial draw collection protocol. This combined approach addresses the low-abundance challenge of direct detection while covering the three most clinically significant co-infection genera in a single testing strategy. For clinicians working through complex acute presentations, testing these three pathogens in parallel rather than sequentially reflects how they are transmitted and how they present clinically.

Evaluating Specialty Laboratory Options

Not all specialty laboratories approach tick-borne disease testing in the same way. When evaluating a laboratory for a tick bite testing protocol, the following questions are clinically relevant:

• Has the laboratory published peer-reviewed studies validating its testing methods? Are those publications available for review?
• What is the antigen source used in serological assays, clinical isolates or recombinant antigens? What are the sensitivity and specificity implications of each for the population being tested?
• What detection technology is in use, PCR, digital PCR, FISH, culture, and what are the known sensitivity and species-coverage differences across methods? Digital PCR tick-borne disease testing offers meaningful sensitivity advantages over standard qPCR in low-pathogen-burden settings.
• Does the laboratory’s testing cover all relevant species of Borrelia, Babesia, and Bartonella, or only the most commonly referenced strains?

Galaxy Diagnostics is backed by more than 450 peer-reviewed publications and uses a disclosed, multiplexed dPCR platform with absolute quantification [15, 16]. The laboratory’s antigen sources, validation methodology, and test performance data are available to clinicians on request. Learn more at the Suspected Tick-Borne Bundle page on galaxydx.com.

Disclosure: The Lyme Borrelia Direct Detect (urine antigen test) and BBB Direct Detect (dPCR) are Galaxy Diagnostics laboratory developed tests (LDTs). This content is intended for educational purposes only and does not constitute medical advice, treatment guidance, or diagnostic guarantees.